Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis.

Syed Shahzad HasanChia Siang KowMuhammad Abdul HadiSyed Tabish Razi ZaidiHamid A Merchant

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2020)

Since there was no increased risk of harm, the use of RAS inhibitors for hypertension and other established clinical indications can be maintained in COVID-19 patients.

Keyphrases

sars cov
coronavirus disease
blood pressure
cardiovascular events
type diabetes
arterial hypertension